Shahneen Sandhu Selected Research

Docetaxel (Taxotere)

4/2024	[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
11/2023	Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
11/2022	PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
1/2021	UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shahneen Sandhu Research Topics

Disease

68	Prostatic Neoplasms (Prostate Cancer) 04/2024 - 12/2010
57	Neoplasms (Cancer) 10/2023 - 05/2011
55	Melanoma (Melanoma, Malignant) 02/2024 - 10/2014
20	Neoplasm Metastasis (Metastasis) 02/2024 - 02/2013
13	Disease Progression 11/2023 - 05/2011
7	Brain Neoplasms (Brain Tumor) 01/2023 - 05/2011
4	Fatigue 04/2024 - 10/2015
4	Pain (Aches) 02/2024 - 01/2018
3	Circulating Neoplastic Cells 01/2024 - 10/2015
3	Merkel Cell Carcinoma 01/2023 - 01/2020
3	Anemia 01/2023 - 10/2015
3	Adenocarcinoma 01/2021 - 05/2011
2	Nausea 04/2024 - 01/2020
2	Hypertension (High Blood Pressure) 01/2023 - 03/2019
2	Pneumonia (Pneumonitis) 10/2021 - 01/2020
2	Colitis 01/2021 - 01/2020
2	Lymphatic Metastasis 11/2020 - 01/2019
2	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 11/2016
1	Constipation 04/2024
1	Thyroiditis 12/2023
1	Type 2 Diabetes Mellitus (MODY) 10/2023
1	Cholangiocarcinoma 10/2023
1	Breast Neoplasms (Breast Cancer) 07/2023
1	Hypophysitis 01/2023
1	Bites and Stings (Sting) 01/2023
1	Lymphoma (Lymphomas) 01/2023
1	Exanthema (Rash) 01/2023

Drug/Important Bio-Agent (IBA)

20	Immune Checkpoint InhibitorsIBA 12/2023 - 12/2015
19	AntigensIBA 04/2024 - 01/2018
16	pembrolizumabIBA 02/2024 - 05/2018
15	NivolumabIBA 10/2023 - 12/2017
13	Androgen Receptors (Androgen Receptor)IBA 04/2024 - 12/2010
13	IpilimumabIBA 01/2023 - 12/2017
11	olaparibIBA 11/2023 - 05/2011
11	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2022 - 05/2011
10	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2017
9	Prostate-Specific Antigen (Semenogelase)IBA 04/2024 - 10/2015
8	enzalutamideIBA 04/2024 - 11/2018
8	Lutetium-177IBA 04/2024 - 01/2018
8	abirateroneIBA 11/2023 - 11/2018
8	Radioisotopes (Radionuclides)IBA 01/2023 - 01/2018
7	Hormones (Hormone)IBA 10/2023 - 05/2011
6	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 02/2013
6	AndrogensIBA 07/2023 - 12/2010
5	Proteins (Proteins, Gene)FDA Link 01/2024 - 11/2018
5	taxaneIBA 07/2023 - 01/2018
5	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 10/2015
4	Docetaxel (Taxotere)FDA Link 04/2024 - 01/2021
4	cabazitaxel FDA Link 04/2024 - 01/2021
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 10/2014
4	trametinibIBA 01/2023 - 10/2014
4	177Lu-PSMA-617IBA 01/2022 - 01/2019
4	RNA (Ribonucleic Acid)IBA 01/2022 - 11/2016
4	Circulating Tumor DNAIBA 11/2020 - 11/2017
3	niraparibIBA 07/2023 - 01/2022
3	B7-H1 AntigenIBA 01/2023 - 01/2020
3	dabrafenibIBA 01/2023 - 01/2020
3	LigandsIBA 01/2022 - 01/2018
3	PlatinumIBA 07/2017 - 10/2013
2	bempegaldesleukinIBA 10/2023 - 10/2020
2	Cell-Free Nucleic AcidsIBA 10/2023 - 01/2017
2	Poly Adenosine Diphosphate RiboseIBA 07/2023 - 01/2020
2	atezolizumabIBA 01/2023 - 01/2021
2	Prednisone (Sone)FDA LinkGeneric 01/2023 - 12/2020
2	ipatasertibIBA 01/2023 - 10/2021
2	Prednisolone (Predate)FDA LinkGeneric 01/2023 - 10/2021
2	AntibodiesIBA 12/2022 - 01/2021
2	RNA Polymerase I (Polymerase I, RNA)IBA 11/2021 - 11/2016
2	CX 5461IBA 11/2021 - 11/2016
2	Mitogen-Activated Protein KinasesIBA 01/2020 - 10/2016
2	SteroidsIBA 03/2019 - 05/2011
2	Phosphotransferases (Kinase)IBA 11/2016 - 03/2015
2	TabletsIBA 10/2016 - 10/2015
1	Gallium-68IBA 04/2024
1	Acetaminophen (Paracetamol)FDA LinkGeneric 02/2024
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2024
1	relatlimabIBA 10/2023
1	Mitochondrial DNA (mtDNA)IBA 10/2023
1	Adenosine (Adenocard)FDA LinkGeneric 07/2023
1	Immunoglobulin G (IgG)IBA 01/2023
1	Abiraterone AcetateIBA 01/2023
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2023
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2023
1	cobimetinibIBA 01/2023
1	Metformin (Glucophage)FDA LinkGeneric 01/2023
1	Transaminases (Aminotransferases)IBA 01/2023
1	FluorineIBA 01/2023
1	antiarrhythmic peptide (AAP)IBA 01/2023
1	spartalizumabIBA 01/2023
1	Programmed Cell Death 1 ReceptorIBA 12/2022

Therapy/Procedure

60	Therapeutics 04/2024 - 12/2010
43	Castration 04/2024 - 12/2010
18	Immunotherapy 01/2023 - 07/2017
12	Drug Therapy (Chemotherapy) 04/2024 - 08/2013
7	Precision Medicine 11/2022 - 01/2018
4	Lymph Node Excision (Lymph Node Dissection) 01/2022 - 01/2019
3	Prostatectomy (Retropubic Prostatectomy) 10/2023 - 01/2021
3	Aftercare (After-Treatment) 01/2023 - 11/2022
2	Retreatment 01/2023 - 01/2020
1	Salvage Therapy 11/2023